IMVT
NASDAQ HealthcareImmunovant, Inc. - Common Stock
Biotechnology
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjรถgren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
๐ Market Data
| Price | $33.88 |
|---|---|
| Volume | 333,507 |
| Market Cap | 6.97B |
| Beta | 0.810 |
| RSI (14-Day) | 22.0 Oversold |
| 200-Day MA | $31.39 |
| 50-Day MA | $39.93 |
| 52-Week High | $45.42 |
| 52-Week Low | $15.22 |
| Forward P/E | -12.28 |
| Price / Book | 9.47 |
๐ฏ Investment Strategy Scores
IMVT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (59/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (18/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find IMVT in your text
Paste any article, transcript, or post โ the tool will extract IMVT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.